These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 23569370

  • 1. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R, Kelleher D, Preece A, Hughes S, Crater G.
    Int J Chron Obstruct Pulmon Dis; 2013; 8():159-67. PubMed ID: 23569370
    [Abstract] [Full Text] [Related]

  • 2. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 4. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D, Tombs L, Preece A, Brealey N, Mehta R.
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [Abstract] [Full Text] [Related]

  • 5. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA.
    Clin Pharmacokinet; 2020 Jan; 59(1):67-79. PubMed ID: 31321713
    [Abstract] [Full Text] [Related]

  • 6. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Mehta R, Green M, Patel B, Wagg J.
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):153-64. PubMed ID: 26739997
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I.
    Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
    [Abstract] [Full Text] [Related]

  • 8. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D.
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [Abstract] [Full Text] [Related]

  • 9. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2016 Dec; 11():971-9. PubMed ID: 27274218
    [Abstract] [Full Text] [Related]

  • 10. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ.
    Am J Respir Crit Care Med; 2020 Jun 15; 201(12):1508-1516. PubMed ID: 32162970
    [Abstract] [Full Text] [Related]

  • 11. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
    Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N.
    Clin Ther; 2014 Jul 01; 36(7):1016-1027.e2. PubMed ID: 24947493
    [Abstract] [Full Text] [Related]

  • 12. Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials.
    Zhai C, Wang F, Xu R, Sun X, Ma W, Wang L.
    Postgrad Med J; 2024 Sep 22; 100(1188):721-729. PubMed ID: 38652265
    [Abstract] [Full Text] [Related]

  • 13. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
    Malerba M, Morjaria JB, Radaeli A.
    Int J Chron Obstruct Pulmon Dis; 2014 Sep 22; 9():687-95. PubMed ID: 25061288
    [Abstract] [Full Text] [Related]

  • 14. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ, Neffen H.
    Chest; 2015 Aug 22; 148(2):397-407. PubMed ID: 25798635
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 22; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 16. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.
    Kelleher DL, Mehta RS, Jean-Francois BM, Preece AF, Blowers J, Crater GD, Thomas P.
    PLoS One; 2012 Oct 22; 7(12):e50716. PubMed ID: 23284643
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A.
    Respir Med; 2014 Dec 22; 108(12):1752-60. PubMed ID: 25458157
    [Abstract] [Full Text] [Related]

  • 18. Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
    Kerwin EM, Boucot IH, Vogelmeier CF, Maltais F, Naya IP, Tombs L, Jones PW, Lipson DA, Keeley T, Bjermer L.
    Ther Adv Respir Dis; 2020 Dec 22; 14():1753466620926949. PubMed ID: 32462979
    [No Abstract] [Full Text] [Related]

  • 19. Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses.
    Iqbal A, Barnes NC, Brooks J.
    Clin Drug Investig; 2015 Oct 22; 35(10):685-8. PubMed ID: 26329916
    [Abstract] [Full Text] [Related]

  • 20. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ, Edin A.
    Ther Adv Respir Dis; 2013 Dec 22; 7(6):311-9. PubMed ID: 24004659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.